AMRI has inked a deal to trade $41 million for contract manufacturer Cedarburg Pharmaceuticals, looking to broaden its capabilities in the sector and home in on API production.
Germany's Evotec has signed a deal to buy up a biopharma asset management company and get its hands on some promising drug candidates, broadening its novel approach to the CRO game by adding some unpartnered assets to its stable of collaborations.
Parexel is stretching its global network of clinical trial supply operations with a new distribution center in Singapore, bringing the facility online to better support studies across the globe.
Indian CRO GVK Biosciences is looking to boost its capabilities in contract manufacturing, planning to build a new plant in its home country while stretching its presence abroad.
A $2.6 billion deal united contract manufacturers Patheon and DSM Pharmaceutical Products, and now the combined company has emerged to do business under the monicker DPx, expecting to bank $2 billion in revenue this year.
BioClinica has come out the other side of its second merger in as many years, absorbing CCBR-Synarc and plotting to shift its focus toward medical imaging and specialty services for clinical trials.
PPD has signed a contract with the U.S. government's Biomedical Advanced Research and Development Authority, agreeing to design and conduct clinical trials for products that protect against bioterrorism and other public health emergencies.
Charles River Laboratories is looking to pad its preclinical prowess, inking a $179 million deal with drugmaker Galapagos for two CRO subsidiaries and a chance to expand its in vitro biology expertise.
Fresh off scoring U.S. certification for its genomics lab, China's WuXi PharmaTech is amping up its lab testing services, buying into Illumina's $1,000 genome technology and teaming up with Pacific Biomarkers to broaden its assay menu.
North Carolina's Clinipace is looking to scale up its global presence, buying out Hong Kong CRO Choice Pharma and planning to merge its operations into a transcontinental player.
Quintiles founder Dennis Gillings and a trio of private equity backers hauled in more than $400 million when the company first went public, and now they're looking to reap nearly $1 billion more in a secondary public offering.
After numerous setbacks and transitional moves, Columbia Laboratories has settled into its new identity as a CRO, closing its first full quarter of CRO revenue and plotting a brighter future.
INC Research is doubling down on the Middle East, buying up a longtime partner to tighten its grip on a region the CRO says is rapidly developing into a go-to market for clinical research.
WuXi PharmaTech boosted its revenue 15.6% last year, and China's largest CRO is expecting to match that growth in the new year, counting on steady demand for manufacturing and a larger share of the U.S. research market.
Early-phase CRO Celerion is expanding its reach into South Korea, partnering up with a local hospital to run trials in the country's fast-growing market for clinical research.
Indiana's Harlan Laboratories has struck up a deal with French CRO Bertin Pharma to pool resources on early development, teaming up to offer drug discovery and translational medicine services.
CRO Charles River Laboratories has selected Exostar to serve as the gatekeeper to its data, tasking the cloud-based service provider with securing its proprietary information.
Netherlands' CRO Cardialysis has reached out to Boston eClinical outfit AG Mednet to oversee data submission and collection for the medical device and drug trials it runs at more than 1200 sites around the world.
Indian CRO GVK Biosciences has become a global player since Sequoia Capital first bought a stake back in 2007, and now the venture capital stalwart is looking to sell its share at more than three times the price, according to The Economic Times.
MPI Research and its CRO partners are a couple months away from cutting the ribbon on their imaging-focused collaboration, and now the three have installed the particle accelerator they say they'll need to stand out among other drug researchers.